Cytomegalovirus inhibition of extrinsic apoptosis determines fitness and resistance to cytotoxic CD8 T cells.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
09 06 2020
Historique:
pubmed: 24 5 2020
medline: 22 8 2020
entrez: 24 5 2020
Statut: ppublish

Résumé

Viral immune evasion is currently understood to focus on deflecting CD8 T cell recognition of infected cells by disrupting antigen presentation pathways. We evaluated viral interference with the ultimate step in cytotoxic T cell function, the death of infected cells. The viral inhibitor of caspase-8 activation (vICA) conserved in human cytomegalovirus (HCMV) and murine CMV (MCMV) prevents the activation of caspase-8 and proapoptotic signaling. We demonstrate the key role of vICA from either virus, in deflecting antigen-specific CD8 T cell-killing of infected cells. vICA-deficient mutants, lacking either UL36 or M36, exhibit greater susceptibility to CD8 T cell control than mutants lacking the set of immunoevasins known to disrupt antigen presentation via MHC class I. This difference is evident during infection in the natural mouse host infected with MCMV, in settings where virus-specific CD8 T cells are adoptively transferred. Finally, we identify the molecular mechanism through which vICA acts, demonstrating the central contribution of caspase-8 signaling at a point of convergence of death receptor-induced apoptosis and perforin/granzyme-dependent cytotoxicity.

Identifiants

pubmed: 32444487
pii: 1914667117
doi: 10.1073/pnas.1914667117
pmc: PMC7293702
doi:

Substances chimiques

Histocompatibility Antigens Class I 0
M36 protein, mouse cytomegalovirus 0
Receptors, Death Domain 0
UL36 protein, Human herpesvirus 1 0
Viral Proteins 0
perforin 1, mouse 0
Perforin 126465-35-8
Granzymes EC 3.4.21.-
CASP8 protein, human EC 3.4.22.-
Casp8 protein, mouse EC 3.4.22.-
Caspase 8 EC 3.4.22.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't Video-Audio Media

Langues

eng

Sous-ensembles de citation

IM

Pagination

12961-12968

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI020211
Pays : United States

Commentaires et corrections

Type : ErratumIn

Déclaration de conflit d'intérêts

The authors declare no competing interest.

Références

J Immunol. 2009 Nov 15;183(10):6819-30
pubmed: 19864595
J Biol Chem. 2005 Feb 11;280(6):4663-73
pubmed: 15569669
J Exp Med. 1999 Nov 1;190(9):1285-96
pubmed: 10544200
Immunology. 2009 Sep;128(1):69-82
pubmed: 19689737
J Virol. 2017 Dec 14;92(1):
pubmed: 29046460
J Immunol. 2014 Jun 15;192(12):5894-905
pubmed: 24808364
N Engl J Med. 1982 Jul 1;307(1):7-13
pubmed: 6281647
J Virol. 2006 Apr;80(8):4200-2
pubmed: 16571839
Front Microbiol. 2016 Jun 09;7:844
pubmed: 27375569
J Virol. 2008 Mar;82(5):2056-64
pubmed: 18094168
J Virol. 2005 Aug;79(15):9492-502
pubmed: 16014912
Viruses. 2017 Sep 02;9(9):
pubmed: 28869497
Methods Mol Biol. 2010;634:421-30
pubmed: 20677001
J Virol. 2000 Sep;74(17):7861-8
pubmed: 10933693
Eur J Immunol. 1997 Dec;27(12):3492-8
pubmed: 9464839
Methods Mol Biol. 2014;1119:59-79
pubmed: 24639218
J Gen Virol. 2011 Jun;92(Pt 6):1279-1291
pubmed: 21325477
Immunity. 1997 Jan;6(1):57-66
pubmed: 9052837
PLoS One. 2011 Feb 03;6(2):e14646
pubmed: 21304910
J Immunol. 2004 Jun 1;172(11):6944-53
pubmed: 15153514
Cell Mol Immunol. 2007 Apr;4(2):91-8
pubmed: 17484802
EMBO J. 1999 Feb 15;18(4):1081-91
pubmed: 10022849
Cell. 1989 Jul 28;58(2):305-15
pubmed: 2473842
Trends Microbiol. 1998 May;6(5):190-7
pubmed: 9614343
Front Cell Infect Microbiol. 2017 Jul 14;7:312
pubmed: 28770171
Immunology. 2011 Jun;133(2):190-6
pubmed: 21517838
J Exp Med. 2000 Nov 20;192(10):1403-14
pubmed: 11085743
J Immunol. 2013 Apr 1;190(7):3399-409
pubmed: 23460738
Proc Natl Acad Sci U S A. 2017 Mar 28;114(13):E2786-E2795
pubmed: 28292903
Cell. 1995 May 19;81(4):505-12
pubmed: 7538907
Nature. 2011 Mar 17;471(7338):368-72
pubmed: 21368762
Virol J. 2013 Jun 17;10:197
pubmed: 23773211
Biotechniques. 2017 Nov 1;63(5):205-214
pubmed: 29185920
J Virol. 2008 Dec;82(23):11637-50
pubmed: 18815306
J Virol. 2010 Feb;84(3):1221-36
pubmed: 19906905
J Virol. 2011 Oct;85(19):10346-53
pubmed: 21813614
J Virol. 2006 Aug;80(15):7613-24
pubmed: 16840340
EMBO J. 1998 Mar 16;17(6):1675-87
pubmed: 9501089
Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):7829-34
pubmed: 11427719
J Immunol. 2005 Dec 15;175(12):8003-10
pubmed: 16339537
J Virol. 2003 May;77(10):5557-70
pubmed: 12719548
Mol Cell Biol. 2000 Jun;20(11):3781-94
pubmed: 10805722
J Immunol. 2006 Sep 1;177(5):3225-34
pubmed: 16920962
J Virol. 1999 Aug;73(8):7056-60
pubmed: 10400809
Cell. 1994 Mar 25;76(6):959-62
pubmed: 8137429
Virology. 2003 Nov 25;316(2):221-33
pubmed: 14644605
PLoS Pathog. 2012;8(12):e1003062
pubmed: 23271968
Nat Med. 1996 Dec;2(12):1361-6
pubmed: 8946836
J Mol Biol. 1995 Mar 31;247(3):443-58
pubmed: 7714900
J Virol. 2002 Jun;76(12):6044-53
pubmed: 12021337
J Exp Med. 1989 Apr 1;169(4):1199-212
pubmed: 2564415

Auteurs

M Zeeshan Chaudhry (MZ)

Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, 38124 Braunschweig, Germany.
Partner site Hannover-Braunschweig, German Center for Infection Research (DZIF), 38124 Braunschweig, Germany.

Rosaely Casalegno-Garduno (R)

Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, 38124 Braunschweig, Germany.

Katarzyna M Sitnik (KM)

Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, 38124 Braunschweig, Germany.

Bahram Kasmapour (B)

Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, 38124 Braunschweig, Germany.

Ann-Kathrin Pulm (AK)

Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, 38124 Braunschweig, Germany.

Ilija Brizic (I)

Department for Histology and Embryology, Faculty of Medicine, University of Rijeka, 51 000 Rijeka, Croatia.
Center for Proteomics, Faculty of Medicine, University of Rijeka, 51 000 Rijeka, Croatia.

Britta Eiz-Vesper (B)

Institute for Transfusion Medicine, Hannover Medical School, 30625 Hannover, Germany.

Andreas Moosmann (A)

DZIF Group Host Control of Viral Latency and Reactivation, Research Unit Gene Vectors, Helmholtz Zentrum München, 80939 Munich, Germany.

Stipan Jonjic (S)

Department for Histology and Embryology, Faculty of Medicine, University of Rijeka, 51 000 Rijeka, Croatia.
Center for Proteomics, Faculty of Medicine, University of Rijeka, 51 000 Rijeka, Croatia.

Edward S Mocarski (ES)

Department of Microbiology and Immunology, Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322.

Luka Cicin-Sain (L)

Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, 38124 Braunschweig, Germany; luka.cicin-sain@helmholtz-hzi.de.
Partner site Hannover-Braunschweig, German Center for Infection Research (DZIF), 38124 Braunschweig, Germany.
Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, 30625 Hannover, Germany.
Centre for Individualized Infection Medicine, 30625 Hannover, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH